---
title: "Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290602707.md"
description: "Wedbush maintained a Buy rating on Prime Medicine (PRME) with an $8.00 price target. LifeSci Capital also issued a Buy rating, while Morgan Stanley previously held a Hold rating."
datetime: "2026-06-23T19:45:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290602707.md)
  - [en](https://longbridge.com/en/news/290602707.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290602707.md)
---

# Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)

Wedbush analyst maintained a Buy rating on Prime Medicine, Inc. yesterday and set a price target of $8.00.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

In addition to Wedbush, Prime Medicine, Inc. also received a Buy from LifeSci Capital’s Cory Jubinville, PhD in a report issued today. However, on June 18, Morgan Stanley maintained a Hold rating on Prime Medicine, Inc. (NASDAQ: PRME).

### Related Stocks

- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Prime Medicine says FDA clears IND for PM577a in Wilson disease trial](https://longbridge.com/en/news/293661316.md)
- [LifeSci Capital Remains a Buy on Prime Medicine, Inc. (PRME)](https://longbridge.com/en/news/292381827.md)
- [Analyst Reiterates Buy on Seanergy Maritime, Sees Upside from Stronger Earnings and Balance Sheet with Unchanged $20 Price Target](https://longbridge.com/en/news/293825646.md)
- [LifeSci Capital Sticks to Their Buy Rating for Liquidia Technologies (LQDA)](https://longbridge.com/en/news/293825271.md)
- [RBC Capital Sticks to Its Buy Rating for Meta Platforms (META)](https://longbridge.com/en/news/293550312.md)